Product Center
On February 23, 2016, it officially signed a contract with China Medical City
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2016-02-23
- Views:
(Summary description)On February 23, 2016, it officially signed a contract with China Medical City
On February 23, 2016, it officially signed a contract with China Medical City
(Summary description)On February 23, 2016, it officially signed a contract with China Medical City
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2016-02-23 10:57
- Views:
Information
Scan the QR code to read on your phone
Relevant information
-
Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvantsOn August 25th, the R&D team of Yither Biotech (Shanghai) Co., Ltd, a wholly-owned subsidiary of Ab&B Bio Tech Co., Ltd (locally referred to as "Zhonghui Bio"), made a breakthrough in the field of innovative adjuvant research and development. The research results were published online in the internationally renowned journal "Journal of Drug Delivery Science and Technology" under the title "Dual functional Emulsifier Based Nano Emulsification Adjuvant Effectively Enhanced Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine in Mice". - Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou 08-14
- Recombinant herpes zoster vaccine (CHO cells) IND application approved 08-13
- IND application for quadrivalent influenza virus subunit vaccine (adjuvant) approved 07-30
- World Influenza Conference 2024 | Decoding new possibilities for the future of influenza vaccines 07-09
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
